Skip to content

Santhera Pharmaceuticals: Vamorlone Long-Term Data

September 24, 2020

On September 22, 2022, Santhera announced its publication of long-term data with vamorlone in Duchenne muscular dystrophy.

This is data extended from their previously published 24-week data and continues to show a reduction in steroid associated safety issues such as stunting of growth, cushingoid appearance (rounded face), hirsutism (excessive hair growth), weight gain and behavioural changes. Duchenne boys receiving vamorolone continue to show clinical improvement.

For more information on this publication please click here.

Defeat Duchenne Canada has funded $1 million towards their VBP15-006 clinical trial program in Canada evaluating vamorolone in very young children aged 2-4 and older boys aged 7-18. We are very excited about this progress and will continue to update you on this program. If you have any questions regarding this information or the vamorolone clinical trial program, please contact:

Nicola Worsfold

Director of Research and Advocacy

[email protected]

Santhera Pharmaceuticals

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs.

Related Articles